| | Author, year | Electronic databases (year) | Number of studies included (number of study population) | Intervention (participants) | Comparison interventions (participants) | Course (d) | Main outcome | Types of participants | Quality assessment | Quality of primary studies |
| | Hu et al., 2009 [13] | CNKI, Wanfang, VIP
(1994–2008) | 12
(950) | DHI + RT
(477) | CDI, XSTI, VI, BC + RT
(473) | 14–21 d | ①② | AIS | Jadad | Poor |
| | Xu et al., 2010 [14] | CNKI, Wanfang, VIP, CBM
(NA) | 9
(996) | DHI | XDI, CXQI HI, RT, DI, CDI, XSTI | 14–30 d | ①② | AIS | Jadad | Poor |
| | Xiong et al., 2014 [15] | CBM, FMJS, CNKI, Wanfang, VIP, duxiu
(2009–2014) | 21
(2725) | DHI | NA | NA | ① | IS | Jadad | Poor |
| | Ye et al., 2010 [16] | CNKI, PubMed
(2004–2009) | 45
(4027) | DHI | CDI, RT, VI, XSTI, CXQI, and so forth | 7–30 d | ① | IS | Jadad | Poor |
| | Yang and Zeng, 2012 [17] | CNKI, Wanfang
(2006–2010) | 27
(2583) | DHI + RT | DSI, CDI + RT | NA | ①② | IS | Cochrane Handbook | B
Grade |
| | Liu et al., 2014 [18] | CNKI, Wanfang
(2004–2014) | 9
(885) | DHI + RT | RT | 7–14 d | ① | AIS | Cochrane Handbook | B or C
Grade |
| | Peng et al., 2010 [19] | Medline, Embase, CBM, CNKI, VIP, Wanfang
(2000–2010) | 29
(3191) | DHI | CDI | 14–30 d | ①②③ | AIS | Cochrane Handbook | B
Grade |
| | Ma et al., 2012 [20] | CBM, VIP, Medline, Cochrane
(up to 2011) | 14
(1112) | DHI + RT | RT | 14–21 d | ①② | AIS | Jadad | Poor |
|
|
DHI, Danhong injection; RT, routine therapy; CDI, Compound Danshen Injection; XSTI, Xuesetong injection; VI, Venoruton injection; BC, black control; XDI, Xiangdan injection; CXQI, Chuanxiongqin injection; HI, hydroxyethyrutin injection; DI, Dextran injection; NA, not available; DSI, Danshen injection; AIS, acute ischemic stroke; IS, ischemic stroke; FMJS, foreign medical journal full-text service.
① Clinical efficiency; ② neurological deficits score; ③ deterioration and mortality.
|
